Dyadic International closed out the week on the back foot — the stock down 6.1% on the week to $0.7228 — but the more interesting development is in the lending market, where short sellers have been cutting exposure at a pace that stands out even for a micro-cap biotech.
Short interest has collapsed from its April peak, and the retreat accelerated into earnings. Estimated shares short fell roughly 77% from a high of ~189,000 on April 1 to just 43,494 by May 12 — a 24% drop in a single week alone. Given the tiny float, even these small absolute numbers matter, but with SI now representing just 0.16% of the free float, bearish positioning is essentially negligible. The lending market reflects that: borrow availability has opened up to more than 5,900% of short interest, meaning for every share currently borrowed, nearly 60 more are sitting unused in the lending pool. Cost to borrow has drifted back to around 0.79% — a long way from the double-digit spike seen briefly in mid-March when it briefly hit 9.4%. The borrow story is definitively loose.
Options tell a quieter story still. The put/call ratio has run at zero for weeks, with the 52-week high a negligible 0.05. There is simply no derivatives-based hedging activity to read into — DYAI's options market is thin to the point of dormancy.
The fundamental context arrives with today's Q1 earnings release. Revenue of $1.11 million beat the $900,000 consensus estimate, though EPS of -$0.05 missed the -$0.04 forecast. The most recent prior earnings event — March 27 — triggered a sharp 5-day move of +23.4%, while the May 11 event produced a -5.7% one-day reaction. The pattern is volatile and directionally inconsistent, which suits the micro-cap territory. Analyst coverage is thin: HC Wainwright has maintained a Buy rating for several years, though the most recent formal target action was in October 2025 when the firm assumed coverage with a $3.00 target — a substantial premium to the current $0.72 close, though also well below earlier $6.00 targets that date back years and should be treated as stale.
The ownership picture is dominated by founder and CEO Mark Emalfarb, who holds 22.6% of shares and added 2.5 million shares as of the latest filing through April 24. That concentration means thin institutional diversity — Vanguard and Geode both show small additions recently, but the float is so limited that passive buying and selling naturally produces outsized percentage moves. The ORTEX short score has eased to 26.7, down from around 27.7 a fortnight ago, consistent with the broader short-position wind-down. The score's rank in the 93rd percentile of the short-score universe reflects where it has been, not where it is heading — a trailing signal rather than a fresh alarm.
What to watch next: the Q1 conference call transcript is already published, and the next earnings event is pencilled in for June 18 — the tone of management commentary on licensing revenue momentum and partnership pipeline will define how the stock trades into summer from its current sub-$1 level.
See the live data behind this article on ORTEX.
Open DYAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
